None available.
At GentiBio, our mission is to develop innovative and safe Treg cell therapies to transform the lives of patients with autoimmune and inflammatory diseases. We are currently evaluating our investigational product, GNTI-122, in early-stage clinical trials to assess its safety, tolerability, and efficacy. GNTI-122 is being developed for the treatment of patients who are newly diagnosed with or at high risk for developing type 1 diabetes.
We understand that patients and families facing serious or life-threatening conditions may seek access to investigational therapies outside of clinical trials. At this time, GentiBio is not offering an expanded access program for GNTI-122.
We believe that the most efficient and scientifically rigorous way to assess the potential of GNTI-122 is through well-controlled studies designed to generate the data required for regulatory review and potential future approval.
We encourage patients and healthcare providers interested in GNTI-122 to consider participation in our clinical trials. Information about our ongoing studies can be found at www.clinicaltrials.gov by searching for “GNTI-122”.